|
IRAK1BP1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.6998003005142E-10 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.87710000268504E-08 |
| Normal-vs-Stage2 |
2.425200E-04 |
| Normal-vs-Stage3 |
7.38279992695823E-10 |
| Normal-vs-Stage4 |
3.33939986774112E-10 |
| Stage1-vs-Stage2 |
7.838600E-01 |
| Stage1-vs-Stage3 |
5.268400E-02 |
| Stage1-vs-Stage4 |
4.664400E-03 |
| Stage2-vs-Stage3 |
1.294960E-01 |
| Stage2-vs-Stage4 |
3.571600E-02 |
| Stage3-vs-Stage4 |
3.705200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
5.89820414731435E-11 |
| Normal-vs-AfricanAmerican |
7.875900E-03 |
| Normal-vs-Asian |
1.93520000002501E-06 |
| Caucasian-vs-AfricanAmerican |
1.845410E-01 |
| Caucasian-vs-Asian |
7.193000E-01 |
| AfricanAmerican-vs-Asian |
3.341400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
9.18639608826766E-11 |
| Normal-vs-Female |
5.2763999836003E-09 |
| Male-vs-Female |
1.697800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.012099997728E-08 |
| Normal-vs-Age(41-60Yrs) |
2.69329999968981E-07 |
| Normal-vs-Age(61-80Yrs) |
1.74079972659058E-10 |
| Normal-vs-Age(81-100Yrs) |
6.943100E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
8.852800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.727580E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
6.102600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
2.680200E-02 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.955600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
6.954000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.5819000000048E-05 |
| Classical-VS-Follicular |
3.258600E-01 |
| Classical-VS-Other |
8.577000E-01 |
| Classical-VS-Normal |
6.52500053988092E-10 |
| Tall-VS-Follicular |
1.390430E-04 |
| Tall-VS-Other |
1.795380E-01 |
| Tall-VS-Normal |
3.60844687463668E-12 |
| Follicular-VS-Other |
8.641000E-01 |
| Follicular-VS-Normal |
3.172900E-04 |
| Other-VS-Normal |
4.401600E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
8.57480000338029E-08 |
| Normal-vs-N1 |
4.71100000010161E-07 |
| N0-vs-N1 |
3.104400E-01 |
|
|
